Innovative personalized medicine in gastric cancer: Time to move forward

Clinical Genetics

Volumn 86, Issue 1, 2014, Pages 37-43

  Lee, J ^a   Kim, K M ^b   Kang, W K ^a   Ou, S H I ^c  

^a 3E 127 Brody Building   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Actionable mutations; Chemotherapy; Gastric cancer; Molecularly targeted agents; Personalized medicine

Indexed keywords

AFATINIB; AZD 4547; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; LAPATINIB; LUMINESPIB; NERATINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RETINOBLASTOMA BINDING PROTEIN 2; TRASTUZUMAB; VASCULOTROPIN; ARID1A PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MET PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; PROCEDURES; STOMACH NEOPLASMS; TRENDS;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901686770     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12408     Document Type: Review

References (58)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011: 61: 69-90.
2. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010: 376: 687-697.
3. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014: 383: 31-39.
4. Hansjochen WW, Van Cutsem E, Oh SC et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014: 32(suppl 3; abstr LBA7).
5. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012: 83: 407-421.
6. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008: 19: 1523-1529.
7. Sheng WQ, Huang D, Ying JM et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013: 24: 2360-2364.
8. Cho J, Jeong J, Sung J et al. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. Ann Surg Oncol 2013: 20 (Suppl 3): S477-S484.
9. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006: 355: 2733-2743.
10. Hecht JR, Bang YJ, Qin S et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC trial. J Clin Oncol 2013: 31(suppl 34; LBA4001).
11. Bang YJ, Xui R, Taroh S et al. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer in Asian population: TyTAN study. J Clin Oncol 2012: 30(suppl 34; abstr 11).
12. Oh DY, Lee KW, Cho JY et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J Clin Oncol 2012: 30(suppl 4; abstr 54).
13. Lee JW, Soung YH, Seo SH et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006: 12: 57-61.
14. MacConaill LE, Campbell CD, Kehoe SM et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009: 4: e7887.
15. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004: 6: 117-127.
16. Fujita T, Doihara H, Kawasaki K et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006: 94: 247-252.
17. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007: 12: 395-402.
18. Lee J, van Hummelen P, Go C et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012: 7: e38892.
19. Shi J, Yao D, Liu W et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012: 12: 50.
20. Chen CT, Kim H, Liska D et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 2012: 11: 660-669.
21. Lee J, Kim S, Kim P et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One 2013: 8: e54644.
22. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001: 411: 355-365.
23. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011: 29: 4803-4810.
24. Shah MA, Wainberg ZA, Catenacci DV et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013: 8: e54014.
25. Catenacci DV, Henderson L, Xiao SY et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011: 1: 573-579.
26. Ha SY, Lee J, Kang SY et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 2013: 26: 1632-1641.
27. Kim MJ, Lee JY, Nehrbass U et al. Detection of melanoma using antibody-conjugated quantum dots in a coculture model for high-throughput screening system. Analyst 2012: 137: 1440-1445.
28. Cunningham D, Al-Batran SE, Davidenko I et al. RILOMET-1: an international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. J Clin Oncol 2013(suppl; abstr TPS4153): 31.
29. Oliner KS, Tang R, Anderson A et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012 (suppl; abstr 4005): 30.
30. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012: 61: 673-684.
31. Kiyose S, Nagura K, Tao H et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 2012: 62: 477-484.
32. Kim MA, Lee HS, Lee HE et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008: 52: 738-746.
33. Dulak AM, Schumacher SE, van Lieshout J et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012: 72: 4383-4393.
34. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013: 14: 490-499.
35. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013: 14: 481-489.
36. Okines AF, Gonzalez de Castro D, Cunningham D et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and TransMAGIC trials. Eur J Cancer 2013: 49: 2116-2125.
37. Pirker R, Pereira JR, Szczesna A et al. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer 2012: 77: 376-382.
38. Luber B, Deplazes J, Keller G et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011: 11: 509.
39. Zhang L, Yang J, Cai J et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep 2013: 3: 2992.
40. Kim YH, Sasaki Y, Lee KH et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: preliminary results. J Clin Oncol 2011: 29(suppl 4; Abstract 87).
41. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006: 24: 4922-4927.
42. Liu Z, Liu L, Li M et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology 2011: 43: 234-238.
43. Katoh M, Katoh M. FGF signaling network in the gastrointestinal tract. Int J Oncol 2006: 29: 163-168.
44. Xie L, Su X, Zhang L et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013: 19: 2572-2583.
45. Jung E-J, Jung E-J, Min SY et al. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 2012: 43: 1559-1566.
46. Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012: 106: 727-732.
47. Su X, Zhan P, Gavine PR et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 2014: 110: 967-975.
48. van Grieken NCT, Aoyma T, Chambers PA et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer 2013: 108: 1495-1501.
49. Miki H, Ohmori M, Perantoni AO et al. K-ras activation in gastric epithelial tumors in Japanese. Cancer Lett 1991: 58: 107-113.
50. Yoo J, Park SY, Robinson RA et al. Ras gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas. Arch Pathol Lab Med 2002: 126: 1096-1100.
51. Corso G, Velho S, Paredes J et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011: 47: 443-451.
52. Mita H, Toyota M, Aoki F et al. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer 2009: 9: 198.
53. Jänne PA, Shaw AT, Pereira JR et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013: 14: 38-47.
54. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011: 43: 1219-1223.
55. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012: 44: 570-574.
56. Abe H, Maeda D, Hino R et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 2012: 461: 367-377.
57. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011: 29: 3968-3976.
58. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010: 28: 780-787.